about
Effect of mature blood-stage Plasmodium parasite sequestration on pathogen biomass in mathematical and in vivo models of malaria.Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.Mice deficient in the putative phospholipid flippase ATP11C exhibit altered erythrocyte shape, anemia, and reduced erythrocyte life span.A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library.Heme oxygenase-1 deficiency alters erythroblastic island formation, steady-state erythropoiesis and red blood cell lifespan in miceHIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria TransmissionWhere have all the parasites gone? Modelling early malaria parasite sequestration dynamicsHIV-1 Mutation and Recombination Rates Are Different in Macrophages and T-cells.Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complicationsIdentifying recombination hot spots in the HIV-1 genome.Reduced erythrocyte susceptibility and increased host clearance of young parasites slows Plasmodium growth in a murine model of severe malaria.Quantifying Parameter and Structural Uncertainty of Dynamic Disease Transmission Models Using MCMC: An Application to Rotavirus Vaccination in England and Wales.A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection.Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo.Host-mediated impairment of parasite maturation during blood-stage Plasmodium infection.Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug AdministrationEstimating the in-vivo HIV template switching and recombination rate.Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Post transplant CMV-specific T-cell immune reconstitution in the absence of global T-cell immunity is associated with a high risk of subsequent virus reactivation.Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.Within-host modeling of blood-stage malariaFunctional cure of HIV: the scale of the challengePlasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cellsPredictors of SIV recrudescence following antiretroviral treatment interruptionQuantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in miceIn Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance
P50
Q30570570-42051C9F-4594-41B1-A29F-81F4753D8326Q31123548-CC9417E0-914C-46CC-8F6C-3FEA641CEE2DQ33888560-BE75BACA-AB18-46EB-B733-1BD83425081DQ35494993-A4BD711E-F1F2-4219-97EE-20C09D6BC645Q35571009-AADA222C-995E-47A5-936F-29C12524FEA3Q35680431-7C3A6C11-E54A-4301-96F0-D16D4E492B8CQ36215894-B602C0FA-2AE5-4D46-8767-00BBCBA61501Q36618471-CDB2F1D8-7277-49D3-8F06-1FC421D2E7B8Q36846057-21173EF7-9676-4FCA-998B-336F38E2A00FQ37227240-0D4577A4-B78E-46AB-A7FC-F758661A66DEQ37644009-479BFDA8-8901-4533-8905-7E76AE4C8CA3Q37744488-03750585-B3AE-4B98-A38A-2AFC274524F8Q38547247-1960312D-268E-42DA-85A0-790B97453000Q38669416-22B9F5A0-64EC-4242-A8D5-A87EF4C674CDQ40070354-01189EEF-C68C-41CF-95EF-88C7BA7A1753Q40148581-1A333E98-D710-4749-9EE3-6F337DEB12FEQ40649128-58511CE8-D371-476F-9355-C1A5C9474B7DQ40862192-51A63F3A-B02E-4BFD-BDB4-04E2C9DAA17EQ41918728-A114E467-FBB8-4405-B2C2-4BD0D37F15B1Q43577477-87B22E3F-3EDF-404D-A9CE-F7919564CB5EQ53693691-99C5DC54-55C9-4964-98B0-E4034E19FAA6Q56337095-DADE919C-8CC1-4751-8B86-A17EAD6AED31Q58586699-331041C6-65E8-4D4C-BC68-D13A2F3B0A18Q64097654-84D8350C-E963-4438-9E30-1068D3BEA755Q83225592-D894FB1C-B528-43E8-A695-AD3BE6C91046Q91271717-58AF2574-315F-44C0-B90E-B0B08E782D5BQ91700481-6BC79F55-243E-4E64-9747-55DB3F4BFFD6
P50
description
investigador
@es
researcher
@en
name
Deborah Cromer
@en
type
label
Deborah Cromer
@en
prefLabel
Deborah Cromer
@en
P31
P496
0000-0002-5276-5094